Finally, there was evidence that the majority of the sacubitril/valsartan treatment effect on the time-to-first event of cardiovascular death or heart failure hospitalization endpoint is explained by the change from baseline in NT-proBNP over time, addressing the fourth Prentice criterion (Level II, criteria iv and v, Table 2). This evidence concerns the gene NPPB and heart failure.